![]() |
市場調查報告書
商品編碼
1727692
基因的共同研究及授權契約:2018年~2025年Genomic Collaboration and Licensing Deals 2018-2025 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
"基因組合作與授權協議" 提供了前所未有的途徑,讓我們能夠全面了解世界領先生物製藥公司達成的基因組協議。
本報告經過全面修訂和更新,提供了 2018 年至 2025 年基因組交易的詳細資訊。它詳細了解並分析了公司達成基因組交易的方式和原因。這些交易通常涉及多個環節,從合作研發開始,到成果商業化結束。
本報告涵蓋合作、開發、研究和授權交易。
本報告包含自 2018 年以來宣布的 639 項基因組交易的完整列表,包括財務條款(如有),以及交易方披露的實際基因組合作交易的在線交易記錄鏈接。此外,報告還收錄了公司及其合作夥伴向美國證券交易委員會提交的合約文件(如有)。
本報告第一章介紹了基因組學交易。
第一章是對報告的介紹。
第二章概述了自2018年以來的基因組學交易趨勢。
第三章概述了自2018年以來的主要基因組學交易。交易按交易金額排序。
第四章列出了在基因組學交易中最活躍的25家公司,並附有簡要摘要,隨後是基因組學交易的完整列表以及公開的合約文件。
第五章對自2018年1月以來簽署和宣布的基因組學交易進行了全面深入的回顧,合約文件已公開發布。
第六章全面深入地回顧了自2018年1月以來簽署和宣布的基因組學合作交易。本章按感興趣的特定基因組學技術類型進行組織。
報告還包含大量圖表,展示了自2018年以來基因組學交易的趨勢和活動。
此外,綜合交易目錄按公司A-Z、交易類型和治療目標進行組織。每個交易標題都透過網頁連結連結到線上交易記錄,並包含合約文件(如有),方便您隨時存取每份交易文件。
基因體學合作與授權交易提供讀者以下主要優勢:
基因體學合作與授權協議包括:
分析合約文件有助於進行盡職調查:
Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the world's leading biopharma companies.
Fully revised and updated, the report provides details of genomic deals from 2018 to 2025.
The report provides a detailed understanding and analysis of how and why companies enter genomic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 639 genomic deals announced since 2018 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of genomic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in genomic dealmaking since 2018.
Chapter 3 provides an overview of the leading genomic deals since 2018. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2018, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2018. The chapter is organized by specific genomic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2018.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:
Genomic Collaboration and Licensing Deals includes:
Analyzing contract agreements allows due diligence of: